Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > SAE'S Discussions

<< Previous

Bullboard Posts

Next >>

Comment by enriquesuaveon Apr 01, 2024 3:02pm

191 Views

Post# 35963437

RE:SAE'S Discussions

All resolved and 90% within a week of treatment. 100% safety achievement.

digitalstone wrote: Great discussions and debates ! Thanks to those with better insight as to what might be happening in the various boards rooms and FDA corridors.
I found the following in the August 29, 2023 2QFinancial Statements:
Question, who is be on the Board of the DSMB? If these independent members reviewed and confirmed the findings ... would they not be liable if the statement were not true?

"Serious Adverse Events

For 60 patients treated in Study II, there have been 9 Serious Adverse Events ("SAEs") reported:

1 - Grade 1 (resolved within 1 day)

2 - Grade 2 (resolved within 1 and 1 days, respectively)

3 - Grade 3 (resolved within 5, 80 and 107 days, respectively)

2 - Grade 4 (resolved within 6 and 8 days, respectively)

1 - Grade 5

Theralase® believes all SAEs reported to date are unrelated to the Study II Drug or Study II Device, as reviewed and confirmed by the independent Data Safety Monitoring Board ("DSMB")."